The phase 3 IMforte trial showed that adding lurbinectedin to atezolizumab maintenance therapy significantly improved both progression-free and overall survival in extensive-stage small cell lung cancer. Tejas Patil, MD, of the University of Colorado Cancer Center emphasized the potential of this approach to expand long-term outcomes for a broader patient population.